Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042571 (vertigo)
 7,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eight parameters of blood coagulation and fibrinolysis, i.e., the levels of fibrinogen, plasminogen, fibrinogen and/or fibrin-degradation products (FDP), alpha 2-macroglobulin, alpha 1-antitrypsin, CI-inactivator, antiplasmin activity and antithrombin activity, were measured in patients with vertigo. Furthermore, the ADP- and collagen-induced platelet aggregations were determined. The results were compared with those for healthy adults. The antiplasmin activity was significantly reduced (p is less than 0.001), the antithrombin activity was significantly reduced (p is less than 0.001) and the platelet aggregation significantly increased (p is less than 0.001), but the levels of fibrinogen, plasminogen, FDP, alpha 2-macroglobulin, alpha 1-antitrypsin and CI-inactivator were not significantly altered. The importance of the coagulation-fibrinolysis system and platelet function in patients with vertigo is discussed.
 ...
PMID:Inhibitors of coagulation-fibrinolysis system and platelet function in patients with vertigo. 242 47

An examination was made of the behaviour of platelet function after a single i.v. injection of 150 mg Buflomedil in 8 non-diabetic vasculopathic patients. The drug was followed by a significant reduction of the platelet aggregability induced by ADP and adrenaline, but not by collagen, and did not alter the percentage of reversible circulating platelet aggregates. Its action was limited in time, since no activity was observed after 24 hr. The drug was also clinically evaluated in 30 patients aged over 80 yr with chronic cerebrovascular insufficiency, following treatment with 100 mg/day i.v. for 20 days, and then 450 mg/day per os for 80 days. Significant improvements were noted in vertigo, tinnitus, lapses of memory, and the ability to remember numbers. The results were less impressive with regard to insomnia, migraine, and asthenia.
 ...
PMID:[Effect of buflomedil on the behavior of platelet aggregation and its clinical evaluation in elderly patients with chronic cerebrovascular insufficiency]. 634 39

Clinical efficacy of tiklid in a dose 500 mg/day and its action on platelet vascular hemostasis were evaluated in 24 patients with cerebrovascular diseases. A 15-day tiklid course promoted a regress in some subjective symptoms (headache, vertigo, walking instability, photopsias, etc.), the objective neurological status being unchanged. Tiklid had a positive influence on some rheological parameters and platelet vascular hemostasis. ADP-induced platelet aggregation, blood fibrinogen levels got reduced. The platelets sensitivity to antiaggregation agent PgI2 in vitro arose. Antiaggregation potential of the vascular wall returned to normal in 33% of patients with initially low or inverse response.
 ...
PMID:[Clinical and blood rheologic effects of ticlid in patients with cerebrovascular diseases]. 830 98

A 64-year-old female receiving clopidogrel and aspirin antiaggregation therapy after percutaneous coronary intervention for non-STEMI myocardial infarction developed nontraumatic bilateral subdural hematoma with dizziness, vertigo and headache. Craniotomy had to be postponed because of reduced ADP platelet aggregability. Four days after clopidogrel withdrawal and transfusion of 12 platelet concentrate units, ADP aggregation transiently normalized and bilateral trepanation with hematoma evacuation was performed. The procedure was followed by excellent neurologic and clinical recovery; however, decreased platelet aggregability was recorded by postoperative day 12 despite strict clopidogrel and other platelet inhibitor withdrawal. Suspicion of Glanzmann thrombastenia was excluded by flow cytometry. Two weeks after neurosurgery, the right femoral vein thrombosis was detected by color doppler ultrasonography and therapy with fractionated heparin was initiated, followed by warfarin. The risk and incidence of hemorrhagic complications of antiaggregation and anticoagulation therapy are discussed. Caution is warranted on prescribing this potentially harmful therapy to older patients, generally burdened with other chronic comorbidities.
 ...
PMID:Nontraumatic bilateral subdural hematoma caused by antiaggregation therapy: case report and review of the literature. 2108 34